

# Didier Leroy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5073921/publications.pdf>

Version: 2024-02-01

21  
papers

2,242  
citations

471509

17  
h-index

713466

21  
g-index

21  
all docs

21  
docs citations

21  
times ranked

2953  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nature Medicine, 2017, 23, 917-928.	30.7	384
2	A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature, 2015, 522, 315-320.	27.8	353
3	The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium: A Comparative Study with Human and Rodent Parasites. PLoS Medicine, 2012, 9, e1001169.	8.4	301
4	A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Science Translational Medicine, 2015, 7, 296ra111.	12.4	254
5	Antimalarial efficacy of MMV390048, an inhibitor of <i>Plasmodium</i> phosphatidylinositol 4-kinase. Science Translational Medicine, 2017, 9, .	12.4	204
6	High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission. Cell Host and Microbe, 2016, 19, 114-126.	11.0	140
7	Activity of Clinically Relevant Antimalarial Drugs on Plasmodium falciparum Mature Gametocytes in an ATP Bioluminescence Transmission Blocking Assay. PLoS ONE, 2012, 7, e35019.	2.5	126
8	Nowhere to hide: interrogating different metabolic parameters of Plasmodium falciparum gametocytes in a transmission blocking drug discovery pipeline towards malaria elimination. Malaria Journal, 2015, 14, 213.	2.3	85
9	Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials. Trends in Parasitology, 2021, 37, 709-721.	3.3	53
10	A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria. BMC Medicine, 2017, 15, 181.	5.5	49
11	Defining the biology component of the drug discovery strategy for malaria eradication. Trends in Parasitology, 2014, 30, 478-490.	3.3	41
12	Discovering New Transmission-Blocking Antimalarial Compounds: Challenges and Opportunities. Trends in Parasitology, 2016, 32, 669-681.	3.3	40
13	A chemical susceptibility profile of the <i>Plasmodium falciparum</i> transmission stages by complementary cell-based gametocyte assays. Journal of Antimicrobial Chemotherapy, 2016, 71, 1148-1158.	3.0	37
14	Fueling Open Innovation for Malaria Transmission-Blocking Drugs: Hundreds of Molecules Targeting Early Parasite Mosquito Stages. Frontiers in Microbiology, 2019, 10, 2134.	3.5	31
15	Transmission-blocking drugs for malaria elimination. Trends in Parasitology, 2022, 38, 390-403.	3.3	30
16	The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <i>Plasmodium falciparum</i> parasite resistance. Science Translational Medicine, 2021, 13, .	12.4	25
17	Modelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmission. Scientific Reports, 2017, 7, 17680.	3.3	22
18	African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker. Malaria Journal, 2019, 18, 126.	2.3	22

#	ARTICLE	IF	CITATIONS
19	Host-directed therapy, an untapped opportunity for antimalarial intervention. <i>Cell Reports Medicine</i> , 2021, 2, 100423.	6.5	19
20	Setting Our Sights on Infectious Diseases. <i>ACS Infectious Diseases</i> , 2020, 6, 3-13.	3.8	17
21	How to tackle antimalarial resistance?. <i>EMBO Molecular Medicine</i> , 2017, 9, 133-134.	6.9	9